Anterogen.Co.Ltd (065660) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.003x

Based on the latest financial reports, Anterogen.Co.Ltd (065660) has a cash flow conversion efficiency ratio of 0.003x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩281.98 Million ≈ $191.09K USD) by net assets (₩90.04 Billion ≈ $61.02 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Anterogen.Co.Ltd balance sheet quality to measure how much of total assets are equity-financed.

Anterogen.Co.Ltd - Cash Flow Conversion Efficiency Trend (2014–2024)

This chart illustrates how Anterogen.Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Anterogen.Co.Ltd cash flow quality index to evaluate the quality of earnings relative to operating cash generation.

Anterogen.Co.Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Anterogen.Co.Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
CastleNet Technology TWO:8059	-0.066x
Insumos Agroquimicos SA BA:INAG	-1.082x
Adda Corporation TWO:3071	0.068x
Afluente Transmissão de Energia Elétrica S.A SA:AFLT3	0.067x
Taiwan Chelic Corp Ltd TW:4555	0.019x
Overseas Commerce Ltd TA:OVRS	0.088x
Lee Ku Ind KO:025820	0.156x
ÖKOWORLD AG XETRA:VVV3	0.008x

Annual Cash Flow Conversion Efficiency for Anterogen.Co.Ltd (2014–2024)

The table below shows the annual cash flow conversion efficiency of Anterogen.Co.Ltd from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Anterogen.Co.Ltd.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩110.21 Billion ≈ $74.69 Million	₩-860.38 Million ≈ $-583.06K	-0.008x	+49.17%
2023-12-31	₩129.44 Billion ≈ $87.72 Million	₩-1.99 Billion ≈ $-1.35 Million	-0.015x	+16.96%
2022-12-31	₩106.79 Billion ≈ $72.37 Million	₩-1.98 Billion ≈ $-1.34 Million	-0.018x	+29.02%
2021-12-31	₩116.87 Billion ≈ $79.20 Million	₩-3.05 Billion ≈ $-2.06 Million	-0.026x	+52.15%
2020-12-31	₩81.07 Billion ≈ $54.94 Million	₩-4.41 Billion ≈ $-2.99 Million	-0.054x	-125.90%
2019-12-31	₩68.39 Billion ≈ $46.35 Million	₩-1.65 Billion ≈ $-1.12 Million	-0.024x	+10.16%
2018-12-31	₩56.07 Billion ≈ $38.00 Million	₩-1.50 Billion ≈ $-1.02 Million	-0.027x	-429.83%
2017-12-31	₩46.61 Billion ≈ $31.58 Million	₩379.21 Million ≈ $256.98K	0.008x	+311.89%
2016-12-31	₩34.02 Billion ≈ $23.06 Million	₩-130.65 Million ≈ $-88.54K	-0.004x	-107.57%
2015-12-31	₩16.64 Billion ≈ $11.28 Million	₩844.49 Million ≈ $572.30K	0.051x	+165.11%
2014-12-31	₩12.96 Billion ≈ $8.78 Million	₩-1.01 Billion ≈ $-684.63K	-0.078x	--

About Anterogen.Co.Ltd

KQ:065660 Korea Pharmaceuticals

Market Cap

$88.56 Million

₩130.68 Billion KRW

Market Cap Rank

#19555 Global

#951 in Korea

Share Price

₩16430.00

Change (1 day)

+10.05%

52-Week Range

₩14930.00 - ₩58000.00

All Time High

₩197700.00